Avantor OmniTop Sample Tubes Offers Adjustable Volume Sampling
Pharmaceutical Technology's In the Lab eNewsletter
The company recently launched its OmniTop Sample Tubes adjustable volume sampling system, a single-use system that allows for exact sampling.
Avantor’s recently launched OmniTop Sample Tubes adjustable volume sampling system (AVSS) is a single-use system that allows for exact sampling in cell and gene therapy production. The system allows for precise small volume samples, which is expected to streamline the bioprocessing sampling process with increased efficiency, reduced volume loss, and lowered contamination risk.
AVSS is designed to precisely collect small-volume samples from the sterile process. It helps eliminate volume loss in the connection lines, making it ideal for critical and high-value product sampling in applications including:
- cell and gene therapy processes
- final fill operations
- glass and single-use bioreactor sampling
The system can used as a single point solution or can be custom configured into manifold designs. It offers volume ranges of 0.5–15.0 mL, allowing for sample collection of only what is needed for analytical testing to meet the exact needs of the process.
Source: Avantor
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
